These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 28609574)

  • 1. Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort.
    Sbidian E; Giboin C; Bachelez H; Paul C; Beylot-Barry M; Dupuy A; Viguier M; Lacour JP; Schmutz JL; Bravard P; Mahé E; Beneton N; Misery L; Delaporte E; Modiano P; Barbarot S; Regnier E; Jullien D; Richard MA; Joly P; Tubach F; Chosidow O
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):2046-2054. PubMed ID: 28609574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
    Phan C; Beauchet A; Burztejn AC; Severino-Freire M; Barbarot S; Girard C; Lasek A; Reguiai Z; Hadj-Rabia S; Abasq C; Brenaut E; Droitcourt C; Perrussel M; Mallet S; Phan A; Lacour JP; Khemis A; Bourrat E; Chaby G; Deborde R; Plantin P; Maruani A; Piram M; Maccari F; Fougerousse AC; Kupfer-Bessaguet I; Balguérie X; Barthelemy H; Martin L; Quiles-Tsimaratos N; Mery-Brossard L; Pallure V; Lons-Danic D; Bouilly-Auvray D; Beylot-Barry M; Puzenat E; Aubin F; Mahé E; ;
    J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Warren RB; Smith CH; Yiu ZZN; Ashcroft DM; Barker JNWN; Burden AD; Lunt M; McElhone K; Ormerod AD; Owen CM; Reynolds NJ; Griffiths CEM
    J Invest Dermatol; 2015 Nov; 135(11):2632-2640. PubMed ID: 26053050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
    Ross C; Marshman G; Grillo M; Stanford T
    Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
    Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG
    J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
    Carrera CG; Dapavo P; Malagoli P; Naldi L; Arancio L; Gaiani F; Egan CG; Di Mercurio M; Cattaneo A
    J Dermatolog Treat; 2018 Aug; 29(5):481-486. PubMed ID: 29058948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
    JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
    Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
    Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
    Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
    JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scalp psoriasis and biologic agents: a retrospective, comparative study from a tertiary psoriasis referral centre.
    Fotiadou C; Lazaridou E; Sotiriou E; Kyrgidis A; Apalla Z; Ioannides D
    J Eur Acad Dermatol Venereol; 2016 Dec; 30(12):2091-2096. PubMed ID: 27406435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M; Joseph GJ; Princic N; Harrison DJ
    J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis.
    Feldman SR; Zhao Y; Zhou H; Herrera V; Tian H; Li Y
    J Manag Care Spec Pharm; 2017 May; 23(5):583-589. PubMed ID: 28448778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
    Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model for assessing the efficiency of biologic drugs in the treatment of moderate to severe psoriasis for one year in clinical practice in Spain.
    Puig L; López-Ferrer A; Vilarrasa E; García I; Fernández-del Olmo R
    Actas Dermosifiliogr; 2016; 107(1):34-43. PubMed ID: 26365029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry.
    Zweegers J; Groenewoud JMM; van den Reek JMPA; Otero ME; van de Kerkhof PCM; Driessen RJB; van Lümig PPM; Njoo MD; Ossenkoppele PM; Mommers JM; Koetsier MIA; Arnold WP; Andriessen MPM; Kuijpers ALA; Berends MAM; Kievit W; de Jong EMGJ
    Br J Dermatol; 2017 Apr; 176(4):1001-1009. PubMed ID: 27579864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study.
    Rungapiromnan W; Mason KJ; Lunt M; McElhone K; Burden AD; Rutter MK; Warren RB; Griffiths CEM; Ashcroft DM;
    J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):769-778. PubMed ID: 31633837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
    Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
    J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
    Reich K; Burden AD; Eaton JN; Hawkins NS
    Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient Preference for Dosing Frequency Based on Prior Biologic Experience.
    Zhang M; Carter C; Olson WH; Johnson MP; Brennem SK; Lee S; Farahi K
    J Drugs Dermatol; 2017 Mar; 16(3):220-226. PubMed ID: 28301617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
    Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.